Anti-infective company Biota announces Relenza royalties of AU$4.5M
30-Oct-2007
Biota CEO, Peter Cook commented, "The Q1 figures are consistent with Biota's expectation that GSK will sell its installed capacity over the year. These are the summer quarter sales in the northern hemisphere and are typically the lowest of the yearâ"
Biota also confirmed that from this quarter, it will retain the full royalty and is no longer obliged to pass on any payment to third parties.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.